A new phase of testing a German vaccine for the Coronavirus

The German pharmacy company "CureVac" announced that it has already started the second phase of clinical trials for its test vaccine against Covid-19.

The company - based in Tübingen in southwestern Germany - said in a statement that a "first participant" was inoculated with the application of a technology specific to Corvac, and is working on an active substance called "messenger ribonucleic acid mRNA", which is a type of intermediate molecule that includes Protein production instructions.

The Curvac researchers provided MRNA with instructions to produce the emerging corona virus protein for use in the anti-virus vaccine, and after vaccination, human cells form this protein, which the body recognizes as a foreign particle, to form antibodies and other immune cells against it, and the first stage began. From a vaccine test in mid-June.

The second phase trials will be conducted in Peru and Panama with the participation of 690 people, and the company intends to inject them with the vaccine twice within a period of 28 days.

It is expected that the full data for this stage will be issued among the elderly who are more vulnerable to infection with Covid-19 "in the last quarter" of the year, as the company stated.

Big step

"The beginning of the second phase of the clinical trial in Peru and Panama makes us take a big step forward in our program to study Covid-19 clinically," said the technical director of the laboratory, Mariola Voutin-Melii.

The third and final phase of vaccine trials is scheduled to start in the last quarter of this year with 30,000 volunteers, and when the vaccine successfully passes the third phase, the company can submit an application to allow it to enter the market.

The "Curvac" company is among dozens of laboratories in the world participating in a race in search of a vaccine to combat the emerging corona virus.

The European Commission has already seized 225 million doses of the potential Curvac vaccine, which is the fourth such agreement entered into by the European Union with various laboratories.